Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth.
PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who are receiving chemotherapy with or without radiation therapy before donor bone marrow transplantation.
研究概览
地位
干预/治疗
详细说明
OBJECTIVES:
- Compare the incidence and severity of oral mucositis in children undergoing NASA-developed light-emitting diode (LED) therapy during a pre-transplantation myeloablative conditioning regimen (chemotherapy with or without radiotherapy) and continuing through the post-bone marrow transplantation (BMT) phase versus LED therapy during the post-BMT phase only.
OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center and cheek being treated (right vs left). Patients are randomized to 1 of 2 schedules of light-emitting diode (LED) therapy.
- Arm I: Patients undergo LED therapy for 71 seconds once daily beginning on day 1 of the myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy and continuing for 14 days after bone marrow transplantation (BMT).
- Arm II: Patients undergo LED therapy as in arm I beginning on the day of BMT (day 0) and continuing for 14 days after BMT.
Photographs are taken of the right and left buccal mucosa at baseline and then every 3 days beginning on day 1 of LED therapy.
Pain and xerostomia are assessed using the Wong-Baker "smiley-face" pain scale at baseline and then periodically for 14 days after BMT.
Patients are followed monthly for 2 years.
PROJECTED ACCRUAL: A total of 80 patients (40 per arm) will be accrued for this study within 2 years.
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- Medical College of Wisconsin Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
- Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy prior to a first allogeneic bone marrow transplantation
PATIENT CHARACTERISTICS:
Age:
- 2 to 18
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Pulmonary:
- No pulmonary dysfunction that would increase significantly the risk of requiring intubation during the first 21 days after transplantation
Other:
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No photophobia
- Must have emotional, cognitive, and mental maturity sufficient to tolerate light-emitting diode therapy application and oral examination without combativeness
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
Chemotherapy:
- See Disease Characteristics
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
Surgery:
- Not specified
Other:
- No concurrent medication that may cause epidermal or ocular photosensitivity
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
研究衡量的是什么?
主要结果指标
结果测量 |
|---|
|
Mean change in oral mucositis index (OMI) score from baseline to maximum score within 14 days posttransplant
|
|
Mean change in pain score from baseline to maximum score within 14 days posttransplant
|
|
Proportion of patients not experiencing ulcerative mucositis within the first 14 days posttransplant
|
次要结果测量
结果测量 |
|---|
|
Time to heal
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
- 疼痛
- 原发性骨髓纤维化
- 复发性儿童小无裂细胞淋巴瘤
- 复发性儿童大细胞淋巴瘤
- 新生骨髓增生异常综合征
- 既往治疗过的骨髓增生异常综合征
- 继发性骨髓增生异常综合征
- 慢性期慢性粒细胞白血病
- 儿童慢性粒细胞白血病
- 儿童骨髓增生异常综合征
- 复发/难治性儿童霍奇金淋巴瘤
- 母细胞期慢性粒细胞白血病
- 复发性慢性粒细胞白血病
- 口腔并发症
- 难治性慢性淋巴细胞白血病
- III期慢性淋巴细胞白血病
- IV期慢性淋巴细胞白血病
- 先前治疗过的儿童横纹肌肉瘤
- 复发性儿童横纹肌肉瘤
- 播散性神经母细胞瘤
- 复发性神经母细胞瘤
- 难治性多发性骨髓瘤
- 难治性毛细胞白血病
- 复发性儿童急性淋巴细胞白血病
- 加速期慢性粒细胞白血病
- 复发性儿童急性髓性白血病
- 骨髓增生异常/骨髓增生性肿瘤,无法分类
- 复发性儿童淋巴母细胞淋巴瘤
- 非典型慢性粒细胞白血病,BCR-ABL1 阴性
- 复发性肾母细胞瘤和其他儿童肾脏肿瘤
- 儿童急性早幼粒细胞白血病 (M3)
- 儿童恶性卵巢生殖细胞瘤
其他相关的 MeSH 术语
其他研究编号
- CDR0000069293
- MCW-HRRC-28600
- MCW-CHW-0070
- NCI-V02-1699
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.